Anti-UBE2L6 Rabbit Monoclonal Antibody for WB, IHC-P, ELISA - O14933

Core Product Specifications and Parameters

Biological Background: UBE2L6 Function and Localization

• UBE2L6 (Ubiquitin/ISG15-conjugating enzyme E2 L6) is also known as UBCH8, RIG-B (retinoic acid-induced gene B), and ubiquitin carrier protein L6.
• It functions as an E2 ubiquitin-conjugating enzyme, catalyzing the covalent attachment of ubiquitin or ISG15 to substrate proteins.
• UBE2L6 participates in E6/E6-AP-mediated ubiquitination of p53/TP53, targeting it for proteasomal degradation.
• It also promotes ubiquitination and subsequent proteasomal degradation of the FLT3 receptor tyrosine kinase.
• At the protein level, UBE2L6 is detected in natural killer cells.
• The protein has a predicted molecular weight of approximately 18 kDa (17769 Da).
• Alternative splicing yields multiple transcript variants, and the protein has been verified by direct protein sequencing and proteomics identification.

Experimental Guidance and Technical Tips

• The immunogen corresponds to a conserved region (amino acids 54–153) of human UBE2L6, which may account for the observed cross-reactivity with mouse and rat orthologs.
• For Western blotting, expect a band near 18 kDa; use appropriate gel percentage and loading controls, and consider validating specificity with knockdown or knockout samples.
• In immunohistochemistry (IHC-P), test the antibody on tissues or cell lines known to express UBE2L6, such as natural killer cells, and optimize antigen retrieval and blocking conditions.
• For ELISA, determine optimal coating concentrations and detection conditions by titration experiments.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers and research laboratories with one-stop access to IVD raw materials, technical services, and consulting support. This UBE2L6 rabbit monoclonal antibody, suitable for ubiquitin-proteasome and oncology studies, is part of our extensive catalog of validated antibodies and ancillary reagents. Our supply capabilities also include customized monoclonal/polyclonal antibody development, bulk reagent provisioning, and sourcing of rare targets to streamline your assay development pipeline.